Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › PALI
SILVERARC CAPITAL MANAGEMENT, LLC position in PALI
PALISADE BIO INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 2,335,602 shares of PALI (PALISADE BIO INC) in its Q3 2026 13F filing — a position valued at US$3.2M, representing 0.40% of its reported portfolio and ranking #47 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed PALI holdings in 2 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's PALI position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in PALI in Q4 2025 at 102,108 shares (US$240K). The position peaked in Q3 2026 at 2,335,602 shares, worth US$3.2M. Across 2 filings, SILVERARC CAPITAL MANAGEMENT, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,335,602 shares valued at US$3.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 102.11K | $239.95K | New |
| Q3 2026 | 2.34M | $3.15M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PALI and 13F data
PALI (PALISADE BIO INC) is a Health Care company. 94 other funds we track also report a position in PALI — the largest reported positions include Soleus Capital Management, L.P. (US$27.3M), B Group, Inc. (US$23.9M), Octagon Capital Advisors LP (US$21.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PALI
- Soleus Capital Management, L.P. 13.06M sh · $27.30M · Q2 2026
- B Group, Inc. 11.41M sh · $23.86M · Q2 2026
- Octagon Capital Advisors LP 10.28M sh · $21.48M · Q2 2026
- Boxer Capital Management, LLC 4.80M sh · $10.03M · Q2 2026
- Squadron Capital Management LLC 3.00M sh · $6.27M · Q2 2026
- GREAT POINT PARTNERS LLC 2.28M sh · $4.78M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 2.26M sh · $4.72M · Q2 2026
- Artia Global Partners LP 1.99M sh · $4.16M · Q2 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 1.73M sh · $3.62M · Q2 2026
- Propel Bio Management, LLC 2.22M sh · $3.00M · Q3 2026
- Ally Bridge Group (NY) LLC 1.23M sh · $2.57M · Q2 2026
- Creek Drive Management Group LLC 680.00K sh · $918.00K · Q3 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held PALI?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed PALI holdings in 2 of the last 4 reported quarters, going back to Q4 2025.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in PALI?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 2.34M shares of PALI (PALISADE BIO INC), valued at $3.15M, representing 0.40% of its reported portfolio and ranking #47.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling PALI?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC newly opened its position in PALI. The position peaked in Q3 2026 at 2.34M shares.
Which other funds hold PALI?
Other major institutional holders of PALI include Soleus Capital Management, L.P., B Group, Inc., Octagon Capital Advisors LP, among 94 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.